The company will use LP as its own fund of 50 million yuan to subscribe to the Suzhou Industrial Park New Yuan Phase II Venture Capital Enterprise (Limited Partnership), and the Suzhou Industrial Park Yuanfu Venture Capital Management Enterprise will be established as the GP. The fund has a duration of 6 years, including investment in the first 3 years and exit in the next 3 years; the fund size is estimated to be 800 million yuan, which is used to invest in growth biopharmaceutical companies with core competitive advantages and potential for listing, and to support the latter by listing Or by mergers and acquisitions to achieve exit. The partnership's annual internal rate of return is 8%.
20 billion medical financial platform has a new model, the company has achieved the target of 12%
On November 28, 2015, the company's board of directors approved the establishment of a medical financial platform plan of not more than 20 billion yuan, and approved the company's investment scale not exceeding 4 billion yuan. The investment direction is centered on the medical health and medical supply chain financial industry, including establishment with financial institutions. Limited partnership to accelerate the transformation of the company's medical business. In addition to this round of investment, the company has invested a total of 490 million yuan, including the investment of 440 million yuan through the asset management plan to acquire the accounts receivable corresponding to the top three hospitals, this time invested 50 million yuan to subscribe to Yuanfu Venture's partnership, the total completed early 12.3% of the plan.
In-depth industrial investment, after the chain equity investment, try venture capital pharmaceutical companies
In April 2016, the company announced that it plans to invest no more than RMB 100 million to subscribe for the equity of Ningbo Ruixiang Limited Partnership Investment Chain Real Estate, which is the first step of equity investment. The new Yuan Venture Capital Partnership, which participated in this time, is an in-depth exploration of industrial investment.
Considering that this investment target is a growth biopharmaceutical company with potential for listing, and withdrawing through listing or merger after 3 years, it is the operation mode of VC/PE, and the overall operation mode of the company begins to take capital in the true sense. Operation is also the company's light asset development approach in the medical services and pharmaceutical sectors. Considering that the company's planned investment quota is huge, the future expansion of the venture capital field is not ruled out.
Transfer of equity in the new Beijing Center project, the real estate project will gradually withdraw
On July 2, 2016, the company intends to transfer the shares of the participating real estate project companies and partnerships to the first credit controller for 1.72 billion yuan, which means that the company will completely withdraw from the new Beijing center project. The project cooperated with Guangda Anshi in the early stage and is expected to have a development cycle of 5 years. It is the only long-term real estate project of the company. In the next two years, the company's real estate business will be completely withdrawn, and the company's business structure will be optimized and transformed into a medical health group.
Financial innovation, valuation reappears, transformation continues, maintain Buy rating
Financial innovation will help the company's transformation and expansion. The financial business sector will be revalued. The company participates in the establishment of a venture capital limited partnership investment bio-pharmaceutical enterprise, indicating that the company's transformation continues to advance and maintains a Buy rating! Risk warning: The plan is not progressing as expected.
Eye Pad,Breathable Non-Woven Mash Eye Pad,Cotton Breathable Mesh Eye Pad,Medical Absorbent Eye Pad
Shaoxing Weijian Medical Supplies Co.,Ltd. , https://www.wetourmedical.com